Tenaya Therapeutics Inc (OQ:TNYA)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 171 Oyster Point Blvd., Suite 500
Tel: N/A
Website: https://www.tenayatherapeutics.com
IR: See website
Key People
Faraz Ali
Chief Executive Officer, Director
Leone D. Patterson
Chief Financial and Business Officer
Timothy Hoey
Chief Scientific Officer
Whittemore Tingley
Chief Medical Officer
Business Overview
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company's advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company's adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Financial Overview
For the three months ended 31 March 2024, Tenaya Therapeutics Inc revenues was not reported. Net loss increased 2% to $32.2M. Higher net loss reflects Interest income decrease of 26% to $1.5M (income), Stock-based Compensation in R&D increase of 27% to $2M (expense), General and administrative - Balancing increase of 5% to $6.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.43 to -$0.40.
Employees: 140 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $163.55M as of Mar 31, 2024
Annual revenue (TTM): $0.00M as of Mar 31, 2024
EBITDA (TTM): -$122.43M as of Mar 31, 2024
Net annual income (TTM): -$124.58M as of Mar 31, 2024
Free cash flow (TTM): -$101.62M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 78,517,534 as of May 6, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.